267 related articles for article (PubMed ID: 32957448)
21. [Diagnostic scintigraphy and effectiveness of 131I radioiodine therapy in differentiated thyroid carcinoma (DTC)].
Bałdys-Waligórska A; Buziak-Bereza M; Huszno B; Wilczak A
Endokrynol Pol; 2006; 57(4):380-5. PubMed ID: 17006840
[TBL] [Abstract][Full Text] [Related]
22. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
23. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
[TBL] [Abstract][Full Text] [Related]
24. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
25. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
26. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I
Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755
[TBL] [Abstract][Full Text] [Related]
27. The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131.
Dardano A; Ballardin M; Caraccio N; Boni G; Traino C; Mariani G; Ferdeghini M; Barale R; Monzani F
Thyroid; 2012 Mar; 22(3):318-24. PubMed ID: 22181338
[TBL] [Abstract][Full Text] [Related]
28. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
29. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.
Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
Durante C; Haddy N; Baudin E; Leboulleux S; Hartl D; Travagli JP; Caillou B; Ricard M; Lumbroso JD; De Vathaire F; Schlumberger M
J Clin Endocrinol Metab; 2006 Aug; 91(8):2892-9. PubMed ID: 16684830
[TBL] [Abstract][Full Text] [Related]
31. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
32. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
[TBL] [Abstract][Full Text] [Related]
33. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer.
Maxon HR
Q J Nucl Med; 1999 Dec; 43(4):313-23. PubMed ID: 10731782
[TBL] [Abstract][Full Text] [Related]
34. 131I therapy of thyroid cancer patients.
Reiners C; Farahati J
Q J Nucl Med; 1999 Dec; 43(4):324-35. PubMed ID: 10731783
[TBL] [Abstract][Full Text] [Related]
35. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
36. Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes.
Livingston GK; Foster AE; Elson HR
J Toxicol Environ Health; 1993; 40(2-3):367-75. PubMed ID: 8230307
[TBL] [Abstract][Full Text] [Related]
37. Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine.
Chow SM; Law SC; Mendenhall WM; Au SK; Yau S; Mang O; Lau WH
Pediatr Blood Cancer; 2004 Feb; 42(2):176-83. PubMed ID: 14752883
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
39. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
40. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
